Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature

Ferri, Clodoveo; Cacoub, Patrice; Mazzaro, Cesare; Roccatello, Dario; Scaini, Patrizia; Sebastiani, Marco; Tavoni, Antonio; Zignego, Anna Linda; Vita, Salvatore De

doi:10.1016/j.autrev.2011.07.005

Cited by 164 publications

(124 citation statements)

References 57 publications

(130 reference statements)

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…[64][65][66] Numerous case reports and case series have documented the safety and efficacy of rituximab in CV. 67 Rituximab also has a steroid sparing effect and there are reports of patients being treated without, or with very short course of glucocorticoids. 65,66,68 Rituximab has become the treatment of choice for life threatening manifestations like gastrointestinal vasculitis.…”

Section: Management Of Mixed Cryoglobulinemiamentioning

confidence: 99%

Hepatotropic Viral Infection Associated Systemic Vasculitides—Hepatitis B Virus Associated Polyarteritis Nodosa and Hepatitis C Virus Associated Cryoglobulinemic Vasculitis

Sharma

2013

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Two hepatotropic viruses have been shown to have causal relationship with systemic vasculitis-hepatitis B with classical polyarteritis nodosa and hepatitis C with cryoglobulinemic vasculitis. The present paper provides an updated overview on the clinical presentations and management of these vasculitides.HBV associated PAN patients have higher weight loss, peripheral neuropathy, mononeuritis multiplex, abdominal pain, gastrointestinal manifestations requiring surgery, cardiomyopathy, orchitis, hypertension, and/or elevated transaminase levels. Microaneurysms are also more common in mesenteric artery. Skin manifestations, however are less common. These patients also have a severe disease as suggested by higher five factor score and higher BVAS. Though relapses are less common, mortality is higher in patients with HBV PAN as compared to non HBV PAN. Plasmapheresis has a role in treatment in clearing off immune complexes.The common clinical manifestations of HCV associated cryoglobulinemic vasculitis are skin lesions, peripheral neuropathy, glomerulonephritis, arthritis, and sicca symptoms. Though combination therapy comprising of pegylated interferon a and ribavirin is the first line of management, immunotherapy is needed for severe or life threatening manifestations. Recent randomized trials have shown the efficacy of rituximab in such situations. ( J CLIN EXP HEPATOL 2013;3:204-212)

show abstract

Section: Management Of Mixed Cryoglobulinemiamentioning

confidence: 99%

Hepatotropic Viral Infection Associated Systemic Vasculitides—Hepatitis B Virus Associated Polyarteritis Nodosa and Hepatitis C Virus Associated Cryoglobulinemic Vasculitis

Sharma

2013

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…Encouraging results have been obtained in open-label studies and single case reports. RTX improves or cures various clinical manifestations of MC, including fatigue, purpura and skin ulcers, arthralgias and arthritis, glomerulonephritis (in about 90% of cases), peripheral neuropathy (in about 75% of cases), and hyperviscosity syndrome [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50] and [51]. RTX was also reported to be effective in some life-threatening cases of gastrointestinal vasculitis [43].…”

Section: Mixed Cryoglobulinemia-associated Glomerulonephritismentioning

confidence: 99%

“…A proposed strategy, in an attempt to delay the relapses, is to administer two more infusions of RTX 1 and 2 months after the standard four week course (4 plus 2 infusion protocol) [39]. Re-treatment with RTX at disease relapse again proved to be effective in most cases [37], [40] and [43] . Maintenance therapy with RTX is rarely reported in MC, and may be taken into consideration in patients with severe chronic nephritic syndrome or abdominal vasculitis.…”

Section: Mixed Cryoglobulinemia-associated Glomerulonephritismentioning

confidence: 99%

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Kattah¹,

Fervenza²,

Roccatello³

2013

Autoimmunity Reviews

View full text Add to dashboard Cite

Rituximab is a monoclonal antibody to the CD20 antigen on B-cells that was initially designed and approved for the treatment of non-Hodgkin's B-cell lymphoma in 1997.In the last 15 years, it has emerged as a potent immunosuppressant for many immune-mediated diseases, beginning initially with rheumatoid arthritis, and now extending into several other fields, including clinical nephrology. Based on recent large clinical trials, it is FDA-approved for the treatment of ANCA-associated vasculitis and continues to be studied in off-label usage for many glomerular diseases, including membranous nephropathy, lupus nephritis, and mixed cryoglobulinemia. It has been used as a treatment in nephrotic syndrome in children and adults, including both minimal change disease and focal segmental glomerulosclerosis. Given its efficacy, tolerability and safety profile in comparison to more conventional treatment regimens, RTX is rapidly emerging as a critical treatment modality in glomerular disease.

show abstract

“…Bir derlemede TNF-a inhibitörü ilaçların HCV infeksiyonu olan hastalarda etkili olduğu ve iyi tolere edildiği belirtilmiştir. HCV ile ilişkili karaciğer hasarının patogenezinde anahtar rol oynayan TNF-a'nın inhibisyonunun olası olumlu sonucu bazı çalışmalarda özetlenmiş, anti-TNF-a ve standard HCV infeksiyonu tedavilerini kapsayan kombine rejimlerin olası olumlu etkilerinin olduğu ortaya atılmıştır (184). Başka bir çalışmada, daha önce tedavi almamış KHC hastalarında IFN ve RBV tedavisine ajuvan tedavi amacıyla 24 hafta boyunca etanersept eklenmiş; etanersept eklenen 19 hastada istatistiksel olarak anlamlı virolojik yanıt artışı ve tedavinin yan etkilerinde azalma saptanmıştır (185).…”

Section: Hcv İnfeksiyonu Ve Biyolojik İlaçlarunclassified

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Mıstık¹,

Aydın²,

Aksoy³

et al. 2015

Klimik Dergisi

View full text Add to dashboard Cite

ÖzetTürk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu, özel konaklarda ve özel durumlarda kronik hepatit yönetimine ilişkin bir uzlaşı raporu hazırlamak üzere bir toplantı düzenlemiştir. Raporda konuyla ilgili literatür ve uluslararası kılavuzlar, hepatit B virusu (HBV) için sırasıyla kompanse ve dekompanse sirozlu hastalarda kronik hepatit B (KHB) tedavisi, karaciğer nakli sonrası HBV infeksiyonunun nüks etmesinden korunma ve nüks gelişen hastalarda tedavi, fülminan hepatit B tedavisi, hemodiyaliz hastalarında KHB teda- AbstractStudy Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis in special hosts and special situations. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as therapy of chronic hepatitis B (CHB) in patients with compensated and decompensated cirrhosis, prevention and therapy of recurrent hepatitis B after liver transplantation, management of fulminant

show abstract

Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature

Cited by 164 publications

References 57 publications

Hepatotropic Viral Infection Associated Systemic Vasculitides—Hepatitis B Virus Associated Polyarteritis Nodosa and Hepatitis C Virus Associated Cryoglobulinemic Vasculitis

Hepatotropic Viral Infection Associated Systemic Vasculitides—Hepatitis B Virus Associated Polyarteritis Nodosa and Hepatitis C Virus Associated Cryoglobulinemic Vasculitis

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Contact Info

Product

Resources

About